Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.

Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings has an office in Bellaire

Bellaire, US (HQ)

210 4710 Bellaire Blvd

Bio-Path Holdings's revenue was reported to be $13 k in FY, 2016

USD

## Net income (Q2, 2017) | (2 m) |

## Market capitalization (08-Dec-2017) | 35 m |

## Cash (30-Jun-2017) | 6.2 m |

Bio-Path Holdings's current market capitalization is $35 m.

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 13 k | |||

## EBIT | (15.7 m) | (4.5 m) | (5.5 m) | (8.5 m) |

## EBIT margin, % | (65192%) | |||

## Interest income | 4 k | 22.6 k | 17.7 k | 12 k |

USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## R&D expense | 107.6 k | 517 k | 424.5 k | 592.5 k | 564.4 k | 992.4 k | 1 m | 1.2 m | 2.3 m | 1 m | 1.5 m |

## General and administrative expense | 786.4 k | 566.6 k | 519.9 k | 849 k | 757 k | 681 k | 970 k | 845 k | |||

## Operating expense total | 510.2 k | 1.3 m | 1.2 m | 1.4 m | 1.1 m | 1.5 m | 1.9 m | 1.9 m | 3 m | 2 m | 2.3 m |

## Interest income | 5.6 k | 6.1 k | 5.7 k | 4.3 k | 5.4 k | 4.8 k | 2 k | 2 k | 4 k | 3 k | 2 k |

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 3.6 m | 13.9 m | 8.9 m | 9.4 m |

## Current Assets | 3.7 m | 14.1 m | 9.6 m | 10.7 m |

## PP&E | 113.1 k | 72 k | 614 k | |

## Total Assets | 5.1 m | 15.5 m | 10.8 m | 12.2 m |

USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 16.8 m | 15.7 m | 14.6 m | 12.5 m | 11.1 m | 9.9 m | 6.5 m | 4.2 m | 11.3 m | 7.1 m | 6.2 m |

## Current Assets | 17.2 m | 16 m | 14.9 m | 12.9 m | 12 m | 10.5 m | 7.8 m | 6.1 m | 12.4 m | 8.4 m | 7.8 m |

## PP&E | 102.8 k | 92.6 k | 82.3 k | 62 k | 51 k | 66 k | 872 k | 797 k | |||

## Total Assets | 18.6 m | 17.4 m | 16.3 m | 14.2 m | 13.3 m | 11.7 m | 8.9 m | 7.1 m | 13.4 m | 10.1 m | 9.4 m |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | (3.3 m) | (4.5 m) | (5.5 m) | (6.8 m) |

## Depreciation and Amortization | 10.3 k | 41.1 k | 43 k | |

## Accounts Payable | (34.3 k) | 267.1 k | 375.4 k | (146 k) |

## Cash From Operating Activities | (2.3 m) | (3.8 m) | (5 m) | (8.1 m) |

USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (504.9 k) | (1.8 m) | (2.9 m) | (1.4 m) | (2.5 m) | (4 m) | (1.9 m) | (3.8 m) | (5.4 m) | (397 k) | (2.4 m) |

## Depreciation and Amortization | 10.3 k | 20.6 k | 30.9 k | 10 k | 21 k | 31 k | 33 k | 108 k | |||

## Accounts Payable | 125.1 k | 38.6 k | (11.7 k) | 54.3 k | 130.2 k | (80.7 k) | (37 k) | (124 k) | (71 k) | (208 k) | (257 k) |

## Cash From Operating Activities | (544.4 k) | (1.6 m) | (2.7 m) | (1.4 m) | (2.8 m) | (4 m) | (2.4 m) | (4.6 m) | (6.5 m) | (1.8 m) | (4.2 m) |

Y, 2017 | |
---|---|

## Financial Leverage | 1.1 x |

Search term - Bio-Path Holdings